Drugs / Felbinac Trometamol
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05085106 | Oct 2020 → Oct 2021 | — | Beijing Tongren Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03617510 | Jul → Nov 2018 | — | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03235778 | Jul 2017 → Mar 2018 | — | Yiling Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03872830 | Mar → Sep 2019 | — | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05297669 | Jul 2021 → Jan 2022 | — | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04526132 | Apr → Dec 2021 | — | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Felbinac trometamol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05085106 ↗ |
| Route | Intravenous | “Felbinac Trometamol Injection will be infused IV as a single dose” NCT03235778 ↗ |